Sidley Represents Crossbow Therapeutics in US$77 Million Series B Financing

Sidley represented Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, in its US$77 million Series B financing. The proceeds will support completion of the CROSSCHECK-001 Phase 1 clinical trial of the company’s lead program, CBX-250, and accelerate development of additional T-Bolt™ immunotherapies.

Crossbow is developing a broad portfolio of novel T-cell engager therapies that target peptide human leukocyte antigen on cancer cells using T-cell receptor mimetic antibodies. These investigational T-Bolt™ molecules are designed to address a wide range of malignancies and have the potential to expand the reach of antibody therapies across many cancer proteins.

The Sidley team was led by Rosemary G. Reilly (Emerging Companies and Venture Capital), and included Riley O’Brien and Emily Ivers (Emerging Companies and Venture Capital); and Talbott Paulsen (M&A).